• Johnson & Johnson posted Q2 2026 net sales of $25.31 billion, up 6.6% year over year.
• Net earnings edged down 0.1% to $5.53 billion, while diluted EPS slipped 0.9% to $2.27.
• Innovative Medicine net sales climbed 7.8% to $16.38 billion, while MedTech rose 4.5% to $8.93 billion.
• Free cash flow was about $8.7 billion, up from $6.21 billion a year earlier.
• Raised 2026 outlook, projecting reported sales of $100.8 billion to $101.4 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715519699) on July 15, 2026, and is solely responsible for the information contained therein.